View
450
Download
0
Category
Tags:
Preview:
DESCRIPTION
Presentation on open source pharmaceutical models from the OSPharma workshop in Bellagio, July 2014.
Citation preview
“open source pharma” !
legal, technical, organizational considerations
it’s inaccurate to call open source pharma open source…
but i’m ok with that.
it’s inaccurate to call open source pharma open source…
but i’m ok with that.
“open source”
open source is not: a magic spell, a verb, or a guarantee.
commons-based peer production
modular granular
integratable
regularly outperforms both the large “firm” and the “unorganized
market” in creating complex, stable software or cultural artifacts.
regularly fails at:
inside the firm, modular, granular, integratable.
outside the firm, lots of efforts within the chevrons.
some CBPP, some PP, some fee for service, some “artisan” open.
outside the firm, yet to demonstrate ability to achieve
modular, granular, integratable to create a submittable drug.
the resources required to make open source knowledge need
not be themselves open source…but they must be
commodities.
knowledge products that come off these platforms are
themselves rarely modular, granular, integratable.
there is a serious potential conflict between individual
privacy risks and open access to the data.
(from health records, .25% probability of re-identification
upon directed attack)
we don’t have a firm to coordinate this process.
which means we are the ones who must build the first version of the modern pharmaceutical system.
which means we must commit to: !
standard formats on our data. investment in annotation.
modularity in our tools. granularity in our tasks.
integration with each other.
Recommended